OPKO Health, Inc. Research and Development Expense
OPKO Health, Inc. (OPK) reported Research and Development Expense of $33.17 million for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-28
- OPKO Health, Inc. research and development expense for the quarter ending 2026-06-30 was $33.17M, a 9.31% increase year-over-year.
- OPKO Health, Inc. research and development expense for the quarter ending 2026-03-31 was $29.20M, a 5.32% decline year-over-year.
- OPKO Health, Inc. research and development expense for the quarter ending 2025-12-31 was $32.77M, a 7.71% increase year-over-year.
- OPKO Health, Inc. research and development expense for the quarter ending 2025-09-30 was $30.08M, a 4.55% increase year-over-year.
- OPKO Health, Inc. research and development expense for fiscal 2025 was $124.03M, a 17.89% increase from fiscal 2024.
- OPKO Health, Inc. research and development expense for fiscal 2024 was $105.21M, a 17.44% increase from fiscal 2023.
- OPKO Health, Inc. research and development expense for fiscal 2023 was $89.59M, a 21.26% increase from fiscal 2022.
- OPKO Health, Inc. research and development expense for fiscal 2022 was $73.89M, a 3.86% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.17M 10-Q/A · filed 2026-08-28 | $62.37M 10-Q/A · filed 2026-08-28 | $95.14M derived: sum of 3 quarters · filed 2026-08-28 | $125.22M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2026-03-31 | $29.20M 10-Q/A · filed 2026-08-28 | $61.97M derived: sum of 2 quarters · filed 2026-08-28 | $92.05M derived: sum of 3 quarters · filed 2026-08-28 | $122.39M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2025-12-31 | $32.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $62.85M derived: sum of 2 quarters · filed 2026-02-26 | $93.19M derived: sum of 3 quarters · filed 2026-08-28 | $124.03M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $30.08M 10-Q · filed 2025-10-29 | $60.42M derived: sum of 2 quarters · filed 2026-08-28 | $91.26M 10-Q · filed 2025-10-29 | $121.69M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2025-06-30 | $30.34M 10-Q/A · filed 2026-08-28 | $61.18M 10-Q/A · filed 2026-08-28 | $91.61M derived: sum of 3 quarters · filed 2026-08-28 | $120.38M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2025-03-31 | $30.84M 10-Q/A · filed 2026-08-28 | $61.27M derived: sum of 2 quarters · filed 2026-08-28 | $90.04M derived: sum of 3 quarters · filed 2026-08-28 | $114.12M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2024-12-31 | $30.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.20M derived: sum of 2 quarters · filed 2026-02-26 | $83.28M derived: sum of 3 quarters · filed 2026-02-26 | $105.21M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $28.77M 10-Q · filed 2025-10-29 | $52.85M derived: sum of 2 quarters · filed 2025-10-29 | $74.79M 10-Q · filed 2025-10-29 | $94.18M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $24.08M 10-Q · filed 2025-07-31 | $46.02M 10-Q · filed 2025-07-31 | $65.41M derived: sum of 3 quarters · filed 2026-02-26 | $84.85M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $21.94M 10-Q · filed 2025-05-01 | $41.33M derived: sum of 2 quarters · filed 2026-02-26 | $60.77M derived: sum of 3 quarters · filed 2026-02-26 | $78.92M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.83M derived: sum of 2 quarters · filed 2026-02-26 | $56.99M derived: sum of 3 quarters · filed 2026-02-26 | $89.59M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $19.43M 10-Q · filed 2024-11-07 | $37.59M derived: sum of 2 quarters · filed 2024-11-07 | $70.20M 10-Q · filed 2024-11-07 | $89.73M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $18.16M 10-Q · filed 2024-08-07 | $50.76M 10-Q · filed 2024-08-07 | $70.29M derived: sum of 3 quarters · filed 2025-03-03 | $89.08M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $32.60M 10-Q · filed 2024-05-07 | $52.13M derived: sum of 2 quarters · filed 2025-03-03 | $70.92M derived: sum of 3 quarters · filed 2025-03-03 | $88.18M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $19.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $38.32M derived: sum of 2 quarters · filed 2025-03-03 | $55.57M derived: sum of 3 quarters · filed 2025-03-03 | $73.89M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $18.79M 10-Q · filed 2023-11-06 | $36.05M derived: sum of 2 quarters · filed 2023-11-06 | $54.36M 10-Q · filed 2023-11-06 | $75.36M derived: sum of 4 quarters · filed 2024-03-01 | ||||
| 2022-06-30 | $17.25M 10-Q · filed 2023-08-03 | $35.57M 10-Q · filed 2023-08-03 | $56.57M derived: sum of 3 quarters · filed 2024-03-01 | $74.88M derived: sum of 4 quarters · filed 2024-03-01 | ||||
| 2022-03-31 | $18.31M 10-Q · filed 2023-05-03 | $39.32M derived: sum of 2 quarters · filed 2024-03-01 | $57.63M derived: sum of 3 quarters · filed 2024-03-01 | $75.85M derived: sum of 4 quarters · filed 2024-03-01 | ||||
| 2021-12-31 | $21.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $39.31M derived: sum of 2 quarters · filed 2024-03-01 | $57.53M derived: sum of 3 quarters · filed 2024-03-01 | $76.85M 10-K · filed 2024-03-01 | ||||
| 2021-09-30 | $18.31M 10-Q · filed 2022-11-08 | $36.53M derived: sum of 2 quarters · filed 2022-11-08 | $55.84M 10-Q · filed 2022-11-08 | $73.30M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $18.22M 10-Q · filed 2022-08-04 | $37.54M 10-Q · filed 2022-08-04 | $54.99M derived: sum of 3 quarters · filed 2023-02-27 | $73.48M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $19.32M 10-Q · filed 2022-05-09 | $36.77M derived: sum of 2 quarters · filed 2023-02-27 | $55.26M derived: sum of 3 quarters · filed 2023-02-27 | $72.87M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $35.95M derived: sum of 2 quarters · filed 2023-02-27 | $53.55M derived: sum of 3 quarters · filed 2023-02-27 | $75.32M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $18.49M 10-Q · filed 2021-10-28 | $36.10M derived: sum of 2 quarters · filed 2021-10-28 | $57.86M 10-Q · filed 2021-10-28 | $80.90M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $17.61M 10-Q · filed 2021-07-29 | $39.37M 10-Q · filed 2021-07-29 | $62.41M derived: sum of 3 quarters · filed 2022-03-01 | $92.42M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $21.76M 10-Q · filed 2021-04-28 | $44.80M derived: sum of 2 quarters · filed 2022-03-01 | $74.81M derived: sum of 3 quarters · filed 2022-03-01 | $103.10M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $53.05M derived: sum of 2 quarters · filed 2022-03-01 | $81.34M derived: sum of 3 quarters · filed 2022-03-01 | $117.87M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $30.02M 10-Q · filed 2020-10-29 | $58.30M derived: sum of 2 quarters · filed 2020-10-29 | $94.83M 10-Q · filed 2020-10-29 | $128.16M derived: sum of 4 quarters · filed 2021-02-18 | ||||
| 2019-06-30 | $28.29M 10-Q · filed 2020-07-31 | $64.82M 10-Q · filed 2020-07-31 | $98.14M derived: sum of 3 quarters · filed 2021-02-18 | $128.30M derived: sum of 4 quarters · filed 2021-02-18 | ||||
| 2019-03-31 | $36.53M 10-Q · filed 2020-05-06 | $69.86M derived: sum of 2 quarters · filed 2021-02-18 | $100.02M derived: sum of 3 quarters · filed 2021-02-18 | $129.23M derived: sum of 4 quarters · filed 2021-02-18 | ||||
| 2018-12-31 | $33.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $63.49M derived: sum of 2 quarters · filed 2021-02-18 | $92.70M derived: sum of 3 quarters · filed 2021-02-18 | $125.59M 10-K · filed 2021-02-18 | ||||
| 2018-09-30 | $30.16M 10-Q · filed 2019-11-05 | $59.37M derived: sum of 2 quarters · filed 2019-11-05 | $92.26M 10-Q · filed 2019-11-05 | $126.50M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $29.21M 10-Q · filed 2019-08-07 | $62.10M 10-Q · filed 2019-08-07 | $96.34M derived: sum of 3 quarters · filed 2020-03-02 | $128.85M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $32.89M 10-Q · filed 2019-05-08 | $67.13M derived: sum of 2 quarters · filed 2020-03-02 | $99.64M derived: sum of 3 quarters · filed 2020-03-02 | $132.76M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $34.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $66.75M derived: sum of 2 quarters · filed 2020-03-02 | $99.88M derived: sum of 3 quarters · filed 2020-03-02 | $126.44M 10-K · filed 2020-03-02 | $125.19M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $32.51M 10-Q · filed 2018-11-09 | $32.33M 10-Q · filed 2017-11-08 | $65.64M derived: sum of 2 quarters · filed 2018-11-09 | $92.19M 10-Q · filed 2018-11-09 | $90.94M 10-Q · filed 2017-11-08 | $122.47M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | $33.13M 10-Q · filed 2018-08-07 | $32.59M 10-Q · filed 2017-08-08 | $59.69M 10-Q · filed 2018-08-07 | $58.62M 10-Q · filed 2017-08-08 | $89.96M derived: sum of 3 quarters · filed 2019-03-01 | $114.39M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $26.56M 10-Q · filed 2018-05-08 | $26.02M 10-Q · filed 2017-05-10 | $56.83M derived: sum of 2 quarters · filed 2019-03-01 | $81.26M derived: sum of 3 quarters · filed 2019-03-01 | $112.61M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $30.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $54.70M derived: sum of 2 quarters · filed 2019-03-01 | $86.05M derived: sum of 3 quarters · filed 2019-03-01 | $113.87M 10-K · filed 2019-03-01 | $111.20M 10-K · filed 2017-03-01 | |||
| 2016-09-30 | $24.42M 10-Q · filed 2017-11-08 | $55.77M derived: sum of 2 quarters · filed 2017-11-08 | $83.59M 10-Q · filed 2017-11-08 | $111.39M derived: sum of 4 quarters · filed 2019-01-29 | ||||
| 2016-06-30 | $31.35M 10-Q · filed 2017-08-08 | $59.17M 10-Q · filed 2017-08-08 | $86.96M derived: sum of 3 quarters · filed 2019-01-29 | $105.90M derived: sum of 4 quarters · filed 2019-01-29 | ||||
| 2016-03-31 | $27.82M 10-Q · filed 2017-05-10 | $55.62M derived: sum of 2 quarters · filed 2019-01-29 | $74.55M derived: sum of 3 quarters · filed 2019-01-29 | $104.12M derived: sum of 4 quarters · filed 2019-01-29 | ||||
| 2015-12-31 | $27.79M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $46.73M derived: sum of 2 quarters · filed 2019-01-29 | $76.30M derived: sum of 3 quarters · filed 2019-01-29 | $101.80M 8-K · filed 2019-01-29 | $99.49M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $18.94M 10-Q · filed 2016-11-07 | $48.51M derived: sum of 2 quarters · filed 2016-11-07 | $74.01M 10-Q · filed 2016-11-07 | $99.84M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $29.57M 10-Q · filed 2016-08-08 | $55.07M 10-Q · filed 2016-08-08 | $80.90M derived: sum of 3 quarters · filed 2017-03-01 | $101.42M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | $25.50M 10-Q · filed 2016-05-09 | $51.33M derived: sum of 2 quarters · filed 2017-03-01 | $71.85M derived: sum of 3 quarters · filed 2017-03-01 | $88.08M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | $25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $46.34M derived: sum of 2 quarters · filed 2017-03-01 | $62.58M derived: sum of 3 quarters · filed 2017-03-01 | $83.57M 10-K · filed 2017-03-01 | ||||
| 2014-09-30 | $20.52M 10-Q · filed 2015-11-09 | $36.75M derived: sum of 2 quarters · filed 2015-11-09 | $57.74M 10-Q · filed 2015-11-09 | $81.09M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $16.23M 10-Q · filed 2015-08-05 | $37.23M 10-Q · filed 2015-08-05 | $60.58M derived: sum of 3 quarters · filed 2016-02-29 | $71.66M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $20.99M 10-Q · filed 2015-05-11 | $44.34M derived: sum of 2 quarters · filed 2016-02-29 | $55.43M derived: sum of 3 quarters · filed 2016-02-29 | $64.99M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $23.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $34.44M derived: sum of 2 quarters · filed 2016-02-29 | $43.99M derived: sum of 3 quarters · filed 2016-02-29 | $53.90M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $11.09M 10-Q · filed 2014-11-07 | $20.64M derived: sum of 2 quarters · filed 2014-11-07 | $30.55M 10-Q · filed 2014-11-07 | $37.13M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | $9.56M 10-Q · filed 2014-08-11 | $19.47M 10-Q · filed 2014-08-11 | $26.05M derived: sum of 3 quarters · filed 2015-02-27 | $29.67M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-03-31 | $9.91M 10-Q · filed 2014-05-09 | $16.49M derived: sum of 2 quarters · filed 2015-02-27 | $20.11M derived: sum of 3 quarters · filed 2015-02-27 | $24.60M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2012-12-31 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $10.20M derived: sum of 2 quarters · filed 2015-02-27 | $14.69M derived: sum of 3 quarters · filed 2015-02-27 | $19.52M 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | $3.62M 10-Q · filed 2013-11-12 | $8.11M derived: sum of 2 quarters · filed 2013-11-12 | $12.94M 10-Q · filed 2013-11-12 | $17.20M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | $4.49M 10-Q · filed 2013-08-09 | $9.32M 10-Q · filed 2013-08-09 | $13.58M derived: sum of 3 quarters · filed 2014-03-03 | $16.88M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | $4.83M 10-Q · filed 2013-05-10 | $9.09M derived: sum of 2 quarters · filed 2014-03-03 | $12.39M derived: sum of 3 quarters · filed 2014-03-03 | $15.10M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2011-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $7.56M derived: sum of 2 quarters · filed 2014-03-03 | $10.26M derived: sum of 3 quarters · filed 2014-03-03 | $11.35M 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | $3.30M 10-Q · filed 2012-11-09 | $6.01M derived: sum of 2 quarters · filed 2012-08-09 | $7.10M 10-Q · filed 2012-11-09 | $9.41M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-06-30 | $2.71M 10-Q · filed 2012-08-09 | $3.15M 10-Q · filed 2011-08-08 | $3.80M 10-Q · filed 2012-08-09 | $4.80M 10-Q · filed 2011-08-08 | $6.11M derived: sum of 3 quarters · filed 2013-03-18 | $7.65M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-03-31 | $1.09M 10-Q · filed 2012-05-10 | $3.40M derived: sum of 2 quarters · filed 2013-03-18 | $4.95M derived: sum of 3 quarters · filed 2013-03-18 | $6.52M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2010-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $3.86M derived: sum of 2 quarters · filed 2013-03-18 | $5.43M derived: sum of 3 quarters · filed 2013-03-18 | $5.95M 10-K · filed 2013-03-18 | ||||
| 2010-09-30 | $1.54M 10-Q · filed 2011-11-09 | $3.12M derived: sum of 2 quarters · filed 2011-11-09 | $3.63M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $1.57M 10-Q · filed 2011-08-08 | $2.90M 10-Q · filed 2011-08-08 | ||||||
| 2009-12-31 | $10.84M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |